Our mission is to ensure the generation of accurate and precise findings.

Contact Info Ta-134/A, Gulshan Badda Link 61383766284 noreply@envato.com
GET UPDATE

Please enter subscribe form shortcode

Why AD?

The prevalence of AD is drastically elevating in the aging society with the lack of early diagnosis and therapy. Diagnosis is now based on the measurement of certain protein aggregates in the brain together with memory tests and in some cases with imaging methods, like CT. In this study, peripheral blood (plasma) and cerebrospinal fluid (CSF) will be analysed by cutting-edge biochemical and computational methods.

Patient involvement:

Early AD, prodromal AD patients with age and gender matched controls will be enrolled in three study sites (Sweden, Spain and Turkey). After signing consent, peripheral blood and cerebrospinal fluid (CSF) will be collected and analysed. Please note that the study is completely anonimized and involved individuals will not have any benefits after participating in the study.

get it sent off immediately. Shot of a dentist inserting a blood sample into a tray
Workflow

Human and animal experiments will be carried out in parallel. In mouse models of poor glymphatic clearance and Alzheimer’s disease, we will examine the metabolite profile by using mass spectrometry. Data will be compared with human databases, thus, a more focused metabolomics and glyconomics analysis will be carried out on human samples. Differences between controls, prodromal and early AD patients will be characterized by bioinformatics methods. The potential beneficial effects of selected metabolites will be verified in cell culture assays. On the other hand, the druggability potential of some selected proteins will also be tested, providing a solid preclinical proof-of-concept for further clinical applications.